SEC Form 4 · accession 0001437749-15-016755
Impax Laboratories, LLC · IPXL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Leslie Z Benet
Director
Period of report
Aug 31, 2015
Accepted (ET)
Sep 1, 2015 · 7:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001003642
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 31, 2015 | M | 3,000 | $18.09 | A | 12,200 | D | |
| Common StockF1 | Aug 31, 2015 | S | 3,000 | $40.92 | D | 9,200 | D | |
| Common Stock | Aug 31, 2015 | M | 3,000 | $20.47 | A | 12,200 | D | |
| Common StockF1 | Aug 31, 2015 | S | 3,000 | $40.92 | D | 9,200 | D | |
| Common Stock | Aug 31, 2015 | M | 3,000 | $25.18 | A | 12,200 | D | |
| Common StockF1 | Aug 31, 2015 | S | 3,000 | $40.92 | D | 9,200 | D | |
| Common Stock | Aug 31, 2015 | M | 3,000 | $23.60 | A | 12,200 | D | |
| Common StockF1 | Aug 31, 2015 | S | 3,000 | $40.92 | D | 9,200 | D | |
| Common Stock | Aug 31, 2015 | M | 2,750 | $29.03 | A | 11,950 | D | |
| Common StockF1 | Aug 31, 2015 | S | 2,750 | $40.92 | D | 9,200 | D | |
| Common Stock | Aug 31, 2015 | M | 2,750 | $27.80 | A | 11,950 | D | |
| Common StockF1 | Aug 31, 2015 | S | 2,750 | $40.92 | D | 9,200 | D | |
| Common Stock | Aug 31, 2015 | M | 2,500 | $6.55 | A | 11,700 | D | |
| Common StockF1 | Aug 31, 2015 | S | 2,500 | $40.92 | D | 9,200 | D | |
| Common Stock | holding | — | — | — | 600 | I | By the Benet Family Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $18.09 | Aug 31, 2015 | M | 3,000 | D | — | Jun 21, 2018 | Common Stock | 3,000 | 0 | D |
| Stock Option (Right to Buy)F2 | $20.47 | Aug 31, 2015 | M | 3,000 | D | — | Oct 25, 2018 | Common Stock | 3,000 | 0 | D |
| Stock Option (Right to Buy)F2 | $25.18 | Aug 31, 2015 | M | 3,000 | D | — | Jan 3, 2019 | Common Stock | 3,000 | 0 | D |
| Stock Option (Right to Buy)F2 | $23.60 | Aug 31, 2015 | M | 3,000 | D | — | Apr 4, 2019 | Common Stock | 3,000 | 0 | D |
| Stock Option (Right to Buy)F2 | $29.03 | Aug 31, 2015 | M | 2,750 | D | — | Jul 11, 2019 | Common Stock | 2,750 | 0 | D |
| Stock Option (Right to Buy)F2 | $27.80 | Aug 31, 2015 | M | 2,750 | D | — | Oct 24, 2019 | Common Stock | 2,750 | 0 | D |
| Stock Option (Right to Buy)F2 | $6.55 | Aug 31, 2015 | M | 2,500 | D | — | May 20, 2019 | Common Stock | 2,500 | 53,500 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold at prices ranging from $40.37 to $41.87 in multiple transactions. The reporting person undertakes to provide to Impax Laboratories, Inc., any security holder of Impax Laboratories, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
- F2100% of the shares subject to the option are fully vested and exercisable.
Remarks
The filing of this Statement shall not be construed as an admission (a) that the person filing this Statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this Statement, or (b) that this Statement is legally required to be filed by such person.